Ligand Pharma (LGND) Tops Q2 EPS by 141c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $87.28 +1.35%
EPS Growth %: -47.4%
Financial Fact:
Discontinued operations: 0
Today's EPS Names:
FRGT, VAPO, CMRE, More
EPS Growth %: -47.4%
Financial Fact:
Discontinued operations: 0
Today's EPS Names:
FRGT, VAPO, CMRE, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.81, $1.41 better than the analyst estimate of $0.40. Revenue for the quarter came in at $18.42 million versus the consensus estimate of $17 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall
- Cassava Sciences (SAVA) Reports Q1, Provides Updates on Phase 3 Trials of Simufilam
- Hawaiian Electric Industries (HE) Misses Q1 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
